In this first segment of a one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, and Bruce Feinberg, DO, address some of the key issues payers face as they make coverage decisions on the new PD-1 drug class of immuno-oncology agents.
Dr Kolodziej, national medical director of oncology strategy for Aetna, points out that prescribing behavior has thus far reflected the indications tested during the clinical trial process and, to a lesser extent, where National Comprehensive Cancer Network (NCCN) places them in the treatment guidelines for melanoma and now non-small cell lung cancer. Similarly, payers’ coverage policies reflect approved labeling and the NCCN recommendations.
If they reach their fullest potential, PD-1 inhibitors may be used to target up to 30 different tumor types, says Dr Feinberg, vice president and chief medical officer of Cardinal Health Specialty Solutions. They both agree that a key challenge to successful treatment outcomes with PD-1 inhibitors and for appropriate coverage decision making will be overcoming the lack of biomarkers to determine who will most benefit with these agents.
Dr Feinberg emphasizes that the FDA labeling and NCCN recommendations restrict use of PD-1 agents to patients who have suffered relapses. He believes that the excitement over this drug class, on both the provider and patient levels, will drive the use of these agents earlier in treatment.
The problem, according to Dr Kolodziej, is that clinical evidence on the optimal use of PD-1 inhibitors may lag behind actual use. Such new drug classes, he thinks, may require reconsideration of the way evidence is collected to help not only informed patient care but also coverage policy.
Watch our related Peer Exchange, Oncology Stakeholders Summit, Spring 2015.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More